CD4 and neoplasm: HDACi enhance the immunotherapy response (135) and augment immunotherapy with PD-1 blockade in melanoma cells (136), inhibit apoptosis of CD4+ T cells within the tumor, upregulate antitumor immune responses and restrict tumor growth (137).